Dr. Ivan M. Borrello, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Virginia Commonwealth University, School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 73
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Virginia Commonwealth University, School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME158526 · MD license D47390
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tampa General Hospital Tampa, FL
Medical groups
- Tampa General Medical Group Inc (355 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 73
- Services billed
- 233
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 70 | 22 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 41 | 13 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 28 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
| Established patient office or other outpatient visit, 30-39 minutes | 21 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Tampa, FL | 51 |
| Lenalidomide | 39 |
| Dexamethasone Other prescribers in Tampa, FL | 25 |
| Revlimid (lenalidomide) | 23 |
| Darzalex Faspro (daratumumab-hyaluronidase-fihj) | 20 |
| Ondansetron Hcl Other prescribers in Tampa, FL | 19 |
| Entecavir | 18 |
| Oxycodone Hcl Other prescribers in Tampa, FL | 14 |
| Venclexta (venetoclax) | 14 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 76 payments worth $82,154 in total to this clinician.
| Genzyme Corporation | $36,598 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $20,753 |
| McKesson Sourcing Services, Inc. | $12,407 |
| AstraZeneca UK Limited | $4,800 |
| Adaptive Biotechnologies Corporation | $4,078 |
| AstraZeneca Pharmaceuticals LP | $2,278 |
| Genetix Biotherapeutics Inc | $431 |
| Gilead Sciences, Inc. | $148 |
| Compensation for services other than consulting (speaking, faculty) | $52,808 |
|---|---|
| Consulting Fee | $20,700 |
| Travel and Lodging | $5,194 |
| Food and Beverage | $3,452 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $10,213 |
| Genzyme Corporation Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $10,213 |
| Genzyme Corporation Jan 16, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $10,213 |
| Regeneron Healthcare Solutions, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $8,170 |
| Regeneron Healthcare Solutions, Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $6,536 |
| McKesson Sourcing Services, Inc. Sep 5, 2025 | Consulting Fee | $5,400 |
| McKesson Sourcing Services, Inc. Mar 8, 2025 | Consulting Fee | $4,200 |
| Adaptive Biotechnologies Corporation Feb 6, 2025 | Consulting Fee clonoSEQ · Devices | $4,000 |
| AstraZeneca UK Limited Oct 9, 2025 | Consulting Fee | $3,200 |
| Genzyme Corporation Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $2,860 |
All 32 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $2,043 |
| Regeneron Healthcare Solutions, Inc. Dec 19, 2025 | Travel and Lodging LYNOZYFIC · HEMATOLOGY AND ONCOLOGY · travel to ATLANTA, GA · in-kind | $172 |
| AstraZeneca Pharmaceuticals LP Dec 12, 2025 | Consulting Fee | $2,000 |
| Regeneron Healthcare Solutions, Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $6,536 |
| Regeneron Healthcare Solutions, Inc. Nov 4, 2025 | Travel and Lodging LYNOZYFIC · HEMATOLOGY AND ONCOLOGY · travel to ATLANTA, GA · in-kind | $640 |
| AstraZeneca UK Limited Oct 29, 2025 | Consulting Fee | $1,600 |
| Regeneron Healthcare Solutions, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $8,170 |
| AstraZeneca UK Limited Oct 9, 2025 | Consulting Fee | $3,200 |
| Regeneron Healthcare Solutions, Inc. Oct 8, 2025 | Travel and Lodging LYNOZYFIC · HEMATOLOGY AND ONCOLOGY · travel to NEW YORK,, NY · in-kind | $304 |
| Regeneron Healthcare Solutions, Inc. Oct 8, 2025 | Travel and Lodging LYNOZYFIC · HEMATOLOGY AND ONCOLOGY · travel to NEW YORK,, NY · in-kind | $148 |
| Regeneron Healthcare Solutions, Inc. Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $1,634 |
| Regeneron Healthcare Solutions, Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $926 |
| McKesson Sourcing Services, Inc. Sep 5, 2025 | Consulting Fee | $5,400 |
| McKesson Sourcing Services, Inc. Sep 5, 2025 | Travel and Lodging travel to Nashville, TN | $282 |
| McKesson Sourcing Services, Inc. Sep 5, 2025 | Travel and Lodging travel to Nashville, TN | $32.10 |
| Genzyme Corporation Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $10,213 |
| Genzyme Corporation Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $10,213 |
| Genzyme Corporation Jun 18, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Jacksonville, FL · in-kind | $583 |
| Genzyme Corporation Jun 18, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Jacksonville, FL · in-kind | $420 |
| Genzyme Corporation Jun 18, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Jacksonville, FL · in-kind | $221 |
| McKesson Sourcing Services, Inc. Mar 8, 2025 | Consulting Fee | $4,200 |
| McKesson Sourcing Services, Inc. Mar 8, 2025 | Travel and Lodging travel to Fort Lauderdale, FL | $510 |
| McKesson Sourcing Services, Inc. Mar 8, 2025 | Travel and Lodging travel to Fort Lauderdale, FL | $383 |
| McKesson Sourcing Services, Inc. Mar 8, 2025 | Travel and Lodging travel to Fort Lauderdale, FL | $96.52 |
| McKesson Sourcing Services, Inc. Mar 8, 2025 | Travel and Lodging travel to Fort Lauderdale, FL | $72.00 |
| McKesson Sourcing Services, Inc. Feb 21, 2025 | Consulting Fee | $300 |
| Genzyme Corporation Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $2,860 |
| Adaptive Biotechnologies Corporation Feb 6, 2025 | Consulting Fee clonoSEQ · Devices | $4,000 |
| Genzyme Corporation Jan 16, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $10,213 |
| Genzyme Corporation Jan 16, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Coral Springs, FL · in-kind | $642 |
| Genzyme Corporation Jan 16, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Coral Springs, FL · in-kind | $435 |
| Genzyme Corporation Jan 16, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Coral Springs, FL · in-kind | $253 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $28,214 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with …
Celgene Corporation - Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Novartis Pharmaceuticals Corporation - A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Celgene Corporation · Active, not recruiting · NCT05827016 - A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with …
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.